Dr Jeremy Braybrooke
BSc, BM, FRCP, PhD
Senior Clinical Research Fellow
Jeremy is a Consultant Medical Oncologist and clinical lead for oncology at University Hospitals Bristol NHS Foundation Trust. He trained in Medical Oncology at the Cancer Research UK Medical Oncology unit in Oxford. During this time he completed a PhD in DNA damage and repair pathways. Jeremy has worked in Bristol since 2003 and developed a large research focussed clinical practice specialising in breast and testicular cancers. Jeremy sits on a NICE Technology Appraisal Committee evaluating new medicines and is a member of the Royal College of Physicians Specialist Advisory Committee for medical oncology training. He is actively involved in clinical research and since 2016 has worked part time as a Senior Clinical Research Fellow within EBCTCG.
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.
Early Breast Cancer Trialists’ Collaborative group (EBCTCG) None., (2021), Lancet Oncol, 22, 1139 - 1150
Imaging modality and frequency in surveillance of stage I seminoma testicular cancer: Results from a randomized, phase III, factorial trial (TRISST).
Joffe JK. et al, (2021), JOURNAL OF CLINICAL ONCOLOGY, 39
Real-world outcomes in patients receiving neo-adjuvant chemotherapy for early-stage breast cancer
McDonald C. et al, (2021), CANCER RESEARCH, 81
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Turner NC. et al, (2020), Lancet Oncol, 21, 1296 - 1308
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials
Hudeček J. et al, (2020), npj Breast Cancer, 6